- Report
- April 2023
- 110 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- December 2022
- 118 Pages
Global
From €4712EUR$4,900USD£4,042GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9615EUR$10,000USD£8,249GBP
Ferumoxytol is a hematological drug used to treat iron deficiency anemia. It is an intravenous iron replacement therapy that is administered in two doses. Ferumoxytol is a superparamagnetic iron oxide nanoparticle that is composed of a ferric oxide core and a dextran coating. It is used to replenish iron stores in the body and is indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.
Ferumoxytol is a relatively new drug in the hematological drug market and is gaining traction due to its efficacy and safety profile. It is a convenient and cost-effective alternative to other intravenous iron replacement therapies.
Some companies in the Ferumoxytol market include AMAG Pharmaceuticals, Inc., Fresenius Kabi USA, LLC, and Vifor Pharma Ltd. Show Less Read more